| 1 | composite | 7,166 |
| 2 | glasgow | 608 |
| 3 | nick | 144 |
| 4 | self-adhesive | 118 |
| 5 | flowable | 87 |
| 6 | high-viscosity | 38 |
| 7 | nanofilled | 33 |
| 8 | methacrylate-based | 31 |
| 9 | nanohybrid | 29 |
| 10 | non-homologous | 22 |
| 11 | dual-cure | 19 |
| 12 | dual-curing | 17 |
| 13 | rotatable | 17 |
| 14 | bis-acryl | 13 |
| 15 | dimethacrylate-based | 13 |
| 16 | dual-cured | 12 |
| 17 | low-shrinkage | 12 |
| 18 | nano-hybrid | 12 |
| 19 | self-adhering | 12 |
| 20 | kuijiening | 11 |
| 21 | nonhomologous | 11 |
| 22 | packable | 11 |
| 23 | platform-switching | 11 |
| 24 | self-cured | 11 |
| 25 | face-centered | 10 |
| 26 | accident-related | 9 |
| 27 | preload-independent | 9 |
| 28 | client-treatment | 8 |
| 29 | polyacid-modified | 8 |
| 30 | brazelton | 7 |
| 31 | hip-specific | 7 |
| 32 | arden | 6 |
| 33 | microfilled | 6 |
| 34 | quartz-fiber | 6 |
| 35 | e/f | 5 |
| 36 | fifth-minute | 5 |
| 37 | high-glycaemic | 5 |
| 38 | pre-hydrolyzed | 5 |
| 39 | rosenbek | 5 |
| 40 | training.the | 5 |
| 41 | bis-gma/tegdma | 4 |
| 42 | low-shrinking | 4 |
| 43 | maud | 4 |
| 44 | physical-health | 4 |
| 45 | physician-derived | 4 |
| 46 | subitem | 4 |
| 47 | triphosphate-biotin | 4 |
| 48 | 15-grade | 3 |
| 49 | 3׳ | 3 |
| 50 | 40-foot | 3 |
| 51 | aorto-ventricular | 3 |
| 52 | bulk-fill | 3 |
| 53 | carborane | 3 |
| 54 | celox-coated | 3 |
| 55 | disease-driven | 3 |
| 56 | dna-peicd | 3 |
| 57 | floorboards | 3 |
| 58 | genmatch | 3 |
| 59 | goliath | 3 |
| 60 | mdp-containing | 3 |
| 61 | nonagermanide | 3 |
| 62 | nondynamic | 3 |
| 63 | outcome-a | 3 |
| 64 | potency/durability | 3 |
| 65 | pre-seed | 3 |
| 66 | resveratrol-affinity | 3 |
| 67 | ribbon-reinforced | 3 |
| 68 | two-carbon | 3 |
| 69 | 10-mdp-containing | 2 |
| 70 | 30-μm | 2 |
| 71 | 3′ | 2 |
| 72 | 5-triphospate | 2 |
| 73 | 9237 | 2 |
| 74 | brantigan | 2 |
| 75 | cusp-replacing | 2 |
| 76 | delaire-type | 2 |
| 77 | dentin-composite | 2 |
| 78 | distress/coping | 2 |
| 79 | efficacy-plus-tolerability | 2 |
| 80 | glascow | 2 |
| 81 | his-bind | 2 |
| 82 | magnetron-sputtered | 2 |
| 83 | medication-soaked | 2 |
| 84 | medium-weight | 2 |
| 85 | non-sitagliptin | 2 |
| 86 | nurse-sensitive | 2 |
| 87 | olympio | 2 |
| 88 | p-h2 | 2 |
| 89 | parietex | 2 |
| 90 | peg-go | 2 |
| 91 | phenol-formaldehyde | 2 |
| 92 | pounds/major | 2 |
| 93 | rd/dysregulated | 2 |
| 94 | rhincodon | 2 |
| 95 | rhinogobio | 2 |
| 96 | shouwu | 2 |
| 97 | sp-frc | 2 |
| 98 | stanmore | 2 |
| 99 | suspension-type | 2 |
| 100 | user-led | 2 |
| 101 | volumatic™ | 2 |
| 102 | -0.107±0.013 | 1 |
| 103 | 0-clamp | 1 |
| 104 | 10-strain | 1 |
| 105 | 2005-003829-31 | 1 |
| 106 | 3-row | 1 |
| 107 | 4-meta | 1 |
| 108 | 46-site | 1 |
| 109 | 7-parameter | 1 |
| 110 | 750-ml | 1 |
| 111 | 750ml | 1 |
| 112 | a-oxog | 1 |
| 113 | abilities.the | 1 |
| 114 | advanta-agsv | 1 |
| 115 | alginate-hydroxyapatite | 1 |
| 116 | aminal | 1 |
| 117 | antigen-level | 1 |
| 118 | au-pt-pd | 1 |
| 119 | aucpoint | 1 |
| 120 | australia-modified | 1 |
| 121 | backbone.the | 1 |
| 122 | balanced-saline | 1 |
| 123 | bile-acid-sequestering | 1 |
| 124 | bladder-rectum | 1 |
| 125 | budesonide-soaked | 1 |
| 126 | c2-p-biphenylethynyl | 1 |
| 127 | ca-phosphate-based | 1 |
| 128 | cathejell | 1 |
| 129 | cement/dentin | 1 |
| 130 | claus-henning | 1 |
| 131 | cocaine-specific | 1 |
| 132 | common-effect | 1 |
| 133 | composite-only | 1 |
| 134 | coupling-agent | 1 |
| 135 | delivery-to-utilization | 1 |
| 136 | distinguishability | 1 |
| 137 | dtpw-based | 1 |
| 138 | dual-braked | 1 |
| 139 | dual-polymerising | 1 |
| 140 | dualcuring | 1 |
| 141 | détresse | 1 |
| 142 | early-mid-and | 1 |
| 143 | ethanol-solvated | 1 |
| 144 | event-primary | 1 |
| 145 | finasteride-altered | 1 |
| 146 | five-variable | 1 |
| 147 | flare-delaying | 1 |
| 148 | follow-up-29 | 1 |
| 149 | gait-specific | 1 |
| 150 | galsgows | 1 |
| 151 | glasgow-pittsburgh | 1 |
| 152 | group,16 | 1 |
| 153 | handling/operation | 1 |
| 154 | his.bind | 1 |
| 155 | hyper-cross-linked | 1 |
| 156 | ice-trial | 1 |
| 157 | iv-primary | 1 |
| 158 | konica-minolta | 1 |
| 159 | laboratory.secondary | 1 |
| 160 | lac-gafcs | 1 |
| 161 | lidocaine-enhanced | 1 |
| 162 | lipid-absorbent | 1 |
| 163 | low-shrink | 1 |
| 164 | lowicryl | 1 |
| 165 | malingered | 1 |
| 166 | mdi/disposable | 1 |
| 167 | mesh/ccs | 1 |
| 168 | ngful | 1 |
| 169 | ni-nta-hp | 1 |
| 170 | ningen | 1 |
| 171 | no-fluoride | 1 |
| 172 | non-creatinine | 1 |
| 173 | nonbipartite | 1 |
| 174 | olfaction-vision | 1 |
| 175 | onda-cryl | 1 |
| 176 | papaverine-soaked | 1 |
| 177 | patient-individualised | 1 |
| 178 | pattern-regularity | 1 |
| 179 | pcsmo | 1 |
| 180 | perichondrodermal | 1 |
| 181 | phase-locked-on | 1 |
| 182 | polihexanide-containing | 1 |
| 183 | postconvulsive | 1 |
| 184 | protocol-independent | 1 |
| 185 | purolite | 1 |
| 186 | questionnaire.primary | 1 |
| 187 | recognition-the | 1 |
| 188 | resinmodified | 1 |
| 189 | retrospectively-validated | 1 |
| 190 | rev-s. | 1 |
| 191 | rpl16-rpl14 | 1 |
| 192 | sa60d3 | 1 |
| 193 | same-appearance | 1 |
| 194 | seed/hay | 1 |
| 195 | self-activating | 1 |
| 196 | semi-cement | 1 |
| 197 | semicarbazide-functionalized | 1 |
| 198 | semitransparent | 1 |
| 199 | solvent-soluble | 1 |
| 200 | subject-performance-based | 1 |
| 201 | surflex | 1 |
| 202 | tio2-mil-125 | 1 |
| 203 | trudie | 1 |
| 204 | tumour.the | 1 |
| 205 | turbidity-based | 1 |
| 206 | ventilator.the | 1 |
| 207 | venturi-type | 1 |
| 208 | vulval-specific | 1 |
| 209 | who-designated | 1 |
| 210 | zirconia/ | 1 |
| 1 | -0.107±0.013 | 1 |
| 2 | 0-clamp | 1 |
| 3 | 10-mdp-containing | 2 |
| 4 | 10-strain | 1 |
| 5 | 15-grade | 3 |
| 6 | 2005-003829-31 | 1 |
| 7 | 3-row | 1 |
| 8 | 30-μm | 2 |
| 9 | 3׳ | 3 |
| 10 | 3′ | 2 |
| 11 | 4-meta | 1 |
| 12 | 40-foot | 3 |
| 13 | 46-site | 1 |
| 14 | 5-triphospate | 2 |
| 15 | 7-parameter | 1 |
| 16 | 750-ml | 1 |
| 17 | 750ml | 1 |
| 18 | 9237 | 2 |
| 19 | a-oxog | 1 |
| 20 | abilities.the | 1 |
| 21 | accident-related | 9 |
| 22 | advanta-agsv | 1 |
| 23 | alginate-hydroxyapatite | 1 |
| 24 | aminal | 1 |
| 25 | antigen-level | 1 |
| 26 | aorto-ventricular | 3 |
| 27 | arden | 6 |
| 28 | au-pt-pd | 1 |
| 29 | aucpoint | 1 |
| 30 | australia-modified | 1 |
| 31 | backbone.the | 1 |
| 32 | balanced-saline | 1 |
| 33 | bile-acid-sequestering | 1 |
| 34 | bis-acryl | 13 |
| 35 | bis-gma/tegdma | 4 |
| 36 | bladder-rectum | 1 |
| 37 | brantigan | 2 |
| 38 | brazelton | 7 |
| 39 | budesonide-soaked | 1 |
| 40 | bulk-fill | 3 |
| 41 | c2-p-biphenylethynyl | 1 |
| 42 | ca-phosphate-based | 1 |
| 43 | carborane | 3 |
| 44 | cathejell | 1 |
| 45 | celox-coated | 3 |
| 46 | cement/dentin | 1 |
| 47 | claus-henning | 1 |
| 48 | client-treatment | 8 |
| 49 | cocaine-specific | 1 |
| 50 | common-effect | 1 |
| 51 | composite | 7,166 |
| 52 | composite-only | 1 |
| 53 | coupling-agent | 1 |
| 54 | cusp-replacing | 2 |
| 55 | delaire-type | 2 |
| 56 | delivery-to-utilization | 1 |
| 57 | dentin-composite | 2 |
| 58 | dimethacrylate-based | 13 |
| 59 | disease-driven | 3 |
| 60 | distinguishability | 1 |
| 61 | distress/coping | 2 |
| 62 | dna-peicd | 3 |
| 63 | dtpw-based | 1 |
| 64 | dual-braked | 1 |
| 65 | dual-cure | 19 |
| 66 | dual-cured | 12 |
| 67 | dual-curing | 17 |
| 68 | dual-polymerising | 1 |
| 69 | dualcuring | 1 |
| 70 | détresse | 1 |
| 71 | e/f | 5 |
| 72 | early-mid-and | 1 |
| 73 | efficacy-plus-tolerability | 2 |
| 74 | ethanol-solvated | 1 |
| 75 | event-primary | 1 |
| 76 | face-centered | 10 |
| 77 | fifth-minute | 5 |
| 78 | finasteride-altered | 1 |
| 79 | five-variable | 1 |
| 80 | flare-delaying | 1 |
| 81 | floorboards | 3 |
| 82 | flowable | 87 |
| 83 | follow-up-29 | 1 |
| 84 | gait-specific | 1 |
| 85 | galsgows | 1 |
| 86 | genmatch | 3 |
| 87 | glascow | 2 |
| 88 | glasgow | 608 |
| 89 | glasgow-pittsburgh | 1 |
| 90 | goliath | 3 |
| 91 | group,16 | 1 |
| 92 | handling/operation | 1 |
| 93 | high-glycaemic | 5 |
| 94 | high-viscosity | 38 |
| 95 | hip-specific | 7 |
| 96 | his-bind | 2 |
| 97 | his.bind | 1 |
| 98 | hyper-cross-linked | 1 |
| 99 | ice-trial | 1 |
| 100 | iv-primary | 1 |
| 101 | konica-minolta | 1 |
| 102 | kuijiening | 11 |
| 103 | laboratory.secondary | 1 |
| 104 | lac-gafcs | 1 |
| 105 | lidocaine-enhanced | 1 |
| 106 | lipid-absorbent | 1 |
| 107 | low-shrink | 1 |
| 108 | low-shrinkage | 12 |
| 109 | low-shrinking | 4 |
| 110 | lowicryl | 1 |
| 111 | magnetron-sputtered | 2 |
| 112 | malingered | 1 |
| 113 | maud | 4 |
| 114 | mdi/disposable | 1 |
| 115 | mdp-containing | 3 |
| 116 | medication-soaked | 2 |
| 117 | medium-weight | 2 |
| 118 | mesh/ccs | 1 |
| 119 | methacrylate-based | 31 |
| 120 | microfilled | 6 |
| 121 | nano-hybrid | 12 |
| 122 | nanofilled | 33 |
| 123 | nanohybrid | 29 |
| 124 | ngful | 1 |
| 125 | ni-nta-hp | 1 |
| 126 | nick | 144 |
| 127 | ningen | 1 |
| 128 | no-fluoride | 1 |
| 129 | non-creatinine | 1 |
| 130 | non-homologous | 22 |
| 131 | non-sitagliptin | 2 |
| 132 | nonagermanide | 3 |
| 133 | nonbipartite | 1 |
| 134 | nondynamic | 3 |
| 135 | nonhomologous | 11 |
| 136 | nurse-sensitive | 2 |
| 137 | olfaction-vision | 1 |
| 138 | olympio | 2 |
| 139 | onda-cryl | 1 |
| 140 | outcome-a | 3 |
| 141 | p-h2 | 2 |
| 142 | packable | 11 |
| 143 | papaverine-soaked | 1 |
| 144 | parietex | 2 |
| 145 | patient-individualised | 1 |
| 146 | pattern-regularity | 1 |
| 147 | pcsmo | 1 |
| 148 | peg-go | 2 |
| 149 | perichondrodermal | 1 |
| 150 | phase-locked-on | 1 |
| 151 | phenol-formaldehyde | 2 |
| 152 | physical-health | 4 |
| 153 | physician-derived | 4 |
| 154 | platform-switching | 11 |
| 155 | polihexanide-containing | 1 |
| 156 | polyacid-modified | 8 |
| 157 | postconvulsive | 1 |
| 158 | potency/durability | 3 |
| 159 | pounds/major | 2 |
| 160 | pre-hydrolyzed | 5 |
| 161 | pre-seed | 3 |
| 162 | preload-independent | 9 |
| 163 | protocol-independent | 1 |
| 164 | purolite | 1 |
| 165 | quartz-fiber | 6 |
| 166 | questionnaire.primary | 1 |
| 167 | rd/dysregulated | 2 |
| 168 | recognition-the | 1 |
| 169 | resinmodified | 1 |
| 170 | resveratrol-affinity | 3 |
| 171 | retrospectively-validated | 1 |
| 172 | rev-s. | 1 |
| 173 | rhincodon | 2 |
| 174 | rhinogobio | 2 |
| 175 | ribbon-reinforced | 3 |
| 176 | rosenbek | 5 |
| 177 | rotatable | 17 |
| 178 | rpl16-rpl14 | 1 |
| 179 | sa60d3 | 1 |
| 180 | same-appearance | 1 |
| 181 | seed/hay | 1 |
| 182 | self-activating | 1 |
| 183 | self-adhering | 12 |
| 184 | self-adhesive | 118 |
| 185 | self-cured | 11 |
| 186 | semi-cement | 1 |
| 187 | semicarbazide-functionalized | 1 |
| 188 | semitransparent | 1 |
| 189 | shouwu | 2 |
| 190 | solvent-soluble | 1 |
| 191 | sp-frc | 2 |
| 192 | stanmore | 2 |
| 193 | subitem | 4 |
| 194 | subject-performance-based | 1 |
| 195 | surflex | 1 |
| 196 | suspension-type | 2 |
| 197 | tio2-mil-125 | 1 |
| 198 | training.the | 5 |
| 199 | triphosphate-biotin | 4 |
| 200 | trudie | 1 |
| 201 | tumour.the | 1 |
| 202 | turbidity-based | 1 |
| 203 | two-carbon | 3 |
| 204 | user-led | 2 |
| 205 | ventilator.the | 1 |
| 206 | venturi-type | 1 |
| 207 | volumatic™ | 2 |
| 208 | vulval-specific | 1 |
| 209 | who-designated | 1 |
| 210 | zirconia/ | 1 |
| 1 | rev-s. | 1 |
| 2 | zirconia/ | 1 |
| 3 | 2005-003829-31 | 1 |
| 4 | p-h2 | 2 |
| 5 | -0.107±0.013 | 1 |
| 6 | sa60d3 | 1 |
| 7 | rpl16-rpl14 | 1 |
| 8 | tio2-mil-125 | 1 |
| 9 | group,16 | 1 |
| 10 | 9237 | 2 |
| 11 | follow-up-29 | 1 |
| 12 | outcome-a | 3 |
| 13 | bis-gma/tegdma | 4 |
| 14 | 4-meta | 1 |
| 15 | konica-minolta | 1 |
| 16 | cocaine-specific | 1 |
| 17 | vulval-specific | 1 |
| 18 | hip-specific | 7 |
| 19 | gait-specific | 1 |
| 20 | nondynamic | 3 |
| 21 | high-glycaemic | 5 |
| 22 | sp-frc | 2 |
| 23 | dna-peicd | 3 |
| 24 | lidocaine-enhanced | 1 |
| 25 | ribbon-reinforced | 3 |
| 26 | pre-seed | 3 |
| 27 | australia-modified | 1 |
| 28 | polyacid-modified | 8 |
| 29 | resinmodified | 1 |
| 30 | budesonide-soaked | 1 |
| 31 | papaverine-soaked | 1 |
| 32 | medication-soaked | 2 |
| 33 | dual-braked | 1 |
| 34 | hyper-cross-linked | 1 |
| 35 | user-led | 2 |
| 36 | nanofilled | 33 |
| 37 | microfilled | 6 |
| 38 | malingered | 1 |
| 39 | finasteride-altered | 1 |
| 40 | face-centered | 10 |
| 41 | magnetron-sputtered | 2 |
| 42 | self-cured | 11 |
| 43 | dual-cured | 12 |
| 44 | subject-performance-based | 1 |
| 45 | ca-phosphate-based | 1 |
| 46 | methacrylate-based | 31 |
| 47 | dimethacrylate-based | 13 |
| 48 | dtpw-based | 1 |
| 49 | turbidity-based | 1 |
| 50 | patient-individualised | 1 |
| 51 | retrospectively-validated | 1 |
| 52 | accident-related | 9 |
| 53 | rd/dysregulated | 2 |
| 54 | who-designated | 1 |
| 55 | celox-coated | 3 |
| 56 | ethanol-solvated | 1 |
| 57 | physician-derived | 4 |
| 58 | semicarbazide-functionalized | 1 |
| 59 | pre-hydrolyzed | 5 |
| 60 | nano-hybrid | 12 |
| 61 | nanohybrid | 29 |
| 62 | early-mid-and | 1 |
| 63 | his-bind | 2 |
| 64 | his.bind | 1 |
| 65 | au-pt-pd | 1 |
| 66 | maud | 4 |
| 67 | same-appearance | 1 |
| 68 | 15-grade | 3 |
| 69 | nonagermanide | 3 |
| 70 | no-fluoride | 1 |
| 71 | phenol-formaldehyde | 2 |
| 72 | low-shrinkage | 12 |
| 73 | recognition-the | 1 |
| 74 | backbone.the | 1 |
| 75 | training.the | 5 |
| 76 | ventilator.the | 1 |
| 77 | tumour.the | 1 |
| 78 | abilities.the | 1 |
| 79 | trudie | 1 |
| 80 | five-variable | 1 |
| 81 | packable | 11 |
| 82 | mdi/disposable | 1 |
| 83 | rotatable | 17 |
| 84 | flowable | 87 |
| 85 | solvent-soluble | 1 |
| 86 | carborane | 3 |
| 87 | balanced-saline | 1 |
| 88 | non-creatinine | 1 |
| 89 | delaire-type | 2 |
| 90 | venturi-type | 1 |
| 91 | suspension-type | 2 |
| 92 | stanmore | 2 |
| 93 | dual-cure | 19 |
| 94 | détresse | 1 |
| 95 | 5-triphospate | 2 |
| 96 | purolite | 1 |
| 97 | 46-site | 1 |
| 98 | composite | 7,166 |
| 99 | dentin-composite | 2 |
| 100 | alginate-hydroxyapatite | 1 |
| 101 | nonbipartite | 1 |
| 102 | fifth-minute | 5 |
| 103 | self-adhesive | 118 |
| 104 | postconvulsive | 1 |
| 105 | nurse-sensitive | 2 |
| 106 | e/f | 5 |
| 107 | cusp-replacing | 2 |
| 108 | platform-switching | 11 |
| 109 | low-shrinking | 4 |
| 110 | kuijiening | 11 |
| 111 | polihexanide-containing | 1 |
| 112 | mdp-containing | 3 |
| 113 | 10-mdp-containing | 2 |
| 114 | claus-henning | 1 |
| 115 | distress/coping | 2 |
| 116 | self-adhering | 12 |
| 117 | bile-acid-sequestering | 1 |
| 118 | dual-curing | 17 |
| 119 | dualcuring | 1 |
| 120 | dual-polymerising | 1 |
| 121 | self-activating | 1 |
| 122 | flare-delaying | 1 |
| 123 | a-oxog | 1 |
| 124 | genmatch | 3 |
| 125 | glasgow-pittsburgh | 1 |
| 126 | goliath | 3 |
| 127 | physical-health | 4 |
| 128 | nick | 144 |
| 129 | rosenbek | 5 |
| 130 | low-shrink | 1 |
| 131 | ice-trial | 1 |
| 132 | perichondrodermal | 1 |
| 133 | aminal | 1 |
| 134 | antigen-level | 1 |
| 135 | cathejell | 1 |
| 136 | bulk-fill | 3 |
| 137 | 750-ml | 1 |
| 138 | 750ml | 1 |
| 139 | ngful | 1 |
| 140 | c2-p-biphenylethynyl | 1 |
| 141 | onda-cryl | 1 |
| 142 | bis-acryl | 13 |
| 143 | lowicryl | 1 |
| 144 | subitem | 4 |
| 145 | bladder-rectum | 1 |
| 146 | 30-μm | 2 |
| 147 | brantigan | 2 |
| 148 | arden | 6 |
| 149 | ningen | 1 |
| 150 | disease-driven | 3 |
| 151 | 10-strain | 1 |
| 152 | cement/dentin | 1 |
| 153 | triphosphate-biotin | 4 |
| 154 | non-sitagliptin | 2 |
| 155 | phase-locked-on | 1 |
| 156 | two-carbon | 3 |
| 157 | rhincodon | 2 |
| 158 | olfaction-vision | 1 |
| 159 | handling/operation | 1 |
| 160 | delivery-to-utilization | 1 |
| 161 | brazelton | 7 |
| 162 | peg-go | 2 |
| 163 | rhinogobio | 2 |
| 164 | olympio | 2 |
| 165 | pcsmo | 1 |
| 166 | ni-nta-hp | 1 |
| 167 | 0-clamp | 1 |
| 168 | aorto-ventricular | 3 |
| 169 | quartz-fiber | 6 |
| 170 | 7-parameter | 1 |
| 171 | pounds/major | 2 |
| 172 | mesh/ccs | 1 |
| 173 | lac-gafcs | 1 |
| 174 | floorboards | 3 |
| 175 | non-homologous | 22 |
| 176 | nonhomologous | 11 |
| 177 | galsgows | 1 |
| 178 | common-effect | 1 |
| 179 | medium-weight | 2 |
| 180 | lipid-absorbent | 1 |
| 181 | preload-independent | 9 |
| 182 | protocol-independent | 1 |
| 183 | coupling-agent | 1 |
| 184 | semi-cement | 1 |
| 185 | client-treatment | 8 |
| 186 | semitransparent | 1 |
| 187 | aucpoint | 1 |
| 188 | 40-foot | 3 |
| 189 | shouwu | 2 |
| 190 | advanta-agsv | 1 |
| 191 | glascow | 2 |
| 192 | glasgow | 608 |
| 193 | 3-row | 1 |
| 194 | surflex | 1 |
| 195 | parietex | 2 |
| 196 | seed/hay | 1 |
| 197 | composite-only | 1 |
| 198 | laboratory.secondary | 1 |
| 199 | event-primary | 1 |
| 200 | iv-primary | 1 |
| 201 | questionnaire.primary | 1 |
| 202 | distinguishability | 1 |
| 203 | efficacy-plus-tolerability | 2 |
| 204 | potency/durability | 3 |
| 205 | resveratrol-affinity | 3 |
| 206 | pattern-regularity | 1 |
| 207 | high-viscosity | 38 |
| 208 | volumatic™ | 2 |
| 209 | 3′ | 2 |
| 210 | 3׳ | 3 |